Portfolio
Vericast accelerates financial institution performance through the power of data, technology and people.
vTv Therapeutics LLC is a clinical-stage biotechnology company engaged in treatments for diabetes.
SIGA is a leader in providing solutions for unmet needs in the estimated $10 billion global health security market.
Vericast
Exchange: Privately held
Chairman and CEO: John O’Malley
HQ: San Antonio, TX
Vericast is the FI performance partner. We help banks and credit unions drive growth, improve efficiency, increase engagement and navigate change through the power of data, technology and people. Our advanced analytics, data-driven insights and integrated solution set enable better execution with agility, precision and scale. That’s why nearly 6,000 financial institutions look to Vericast and our 150 years of financial services expertise to help them achieve more. For more information, visit www.vericast.com or follow Vericast on LinkedIn.
Website: www.vericast.com
vTv Therapeutics LLC
Exchange: NASDAQ
Symbol: VTVT
President & CEO: Paul Sekhri
HQ: High Point, NC
vTv Therapeutics LLC is a clinical-stage biotechnology company with a pipeline of drug candidates led by TTP399, a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes (T1D) patients. vTv announced positive Phase 2 results last year for both of its lead diabetes compounds, TTP273 and TTP399, each of which demonstrated statistically significant reductions in HbA1c. vTv was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration in April 2021 as an oral adjunctive therapy for the treatment of T1D.
Website: www.vtvtherapeutics.com
SIGA Technologies, Inc.
Exchange: OTC
Symbol: SIGA
CEO: Diem Nguyen, Ph.D., M.B.A.
HQ: New York, NY
SIGA is a leader in providing solutions for unmet needs in the estimated $10 billion global health security market. In 2018, the U.S. Food and Drug Administration approved SIGA’s first product, oral TPOXX® (tecovirimat), for the treatment of smallpox, a deadly bioterrorism threat that cannot be addressed through vaccines alone. SIGA has worked closely with the U.S. Government during the development of TPOXX® and has been awarded more than $1.1 billion in procurement and development contracts by the Biomedical Advanced Research and Development Authority of the U.S. Government (BARDA). Most recently, SIGA was awarded in a BARDA contract in excess of $600 million for the maintenance of 1.7 million courses of smallpox antiviral in the strategic national stockpile. SIGA is developing an intravenous formulation of TPOXX and pursuing product and market expansion opportunities including a pediatric formulation, post-exposure prophylaxis indication, and international sales.
Website: www.siga.com